Skip to main content

Table 1 Time to funding and episodes of media coverage for 18 anti-cancer agents and indications in Ontario as of August 1 2005.

From: External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer

Drugξ

Indication

Date Results Announced

Date Funded¥

Elapsed Number of Months€

Episodes of Media Coverage

Number Media Reports Per Month

Liposomal doxorubicin [14]

Relapsed ovarian

21-05-00

01-10-01

16

0

0

Imatinib (PO) [15]

Unresectable GIST

18-05-01

20-02-03

22

2

0.09

Zoledronic acid [16]

Metastatic prostate

02-06-01

01-01-04

31

1

0.03

Zoledronic acid [17]

Metastatic breast

21-10-01

Ongoing

46

1

0.02

Docetaxel [18]

Neoadjuvant breast

10-12-01

01-08-04

32

3

0.09

Anastrazole (PO) [19]

Adjuvant breast

10-12-01

22-02-05

39

33

0.85

Docetaxel [20]

1st line ovarian

18-05-02

Ongoing

38

1

0.03

Liposomal doxorubicin [21]

Metastatic breast

18-05-02

Ongoing

38

1

0.03

TAC [22]

Adjuvant breast

19-05-02

Ongoing

38

6

0.16

Premetrexed [23]

Mesothelioma

20-05-02

Ongoing

38

7

0.18

Vinorelbine/trastuzumab [24]

Metastatic breast

12-12-02

01-08-05

32

0

0

Letrozole (PO) [25]

Adjuvant breast

05-12-03

Ongoing

20

16

0.8

Capecitabine (PO) [26]

Adjuvant colon

06-06-04

Ongoing

16

0

0

Vinorelbine [27]

Adjuvant NSCLC

06-06-04

01-08-05

14

17

1.21

Paclitaxel [28]

Adjuvant NSCLC

06-06-04

Ongoing

14

3

0.21

Bortezomib [29]

Relapsed myeloma

06-06-04

Ongoing

14

13

0.93

Docetaxel [30]

Metastatic prostate

07-06-04

01-08-05

14

17

1.21

Trastuzumab [12–13]

Adjuvant breast

16-05-05

01-08-05

3

51

17

  1. ξDrugs are intravenous unless otherwise noted and are listed in chronologic order from date of results announced.
  2. ¥Data was censored at August 1st 2005. If no funding decision had been made by this date, time to funding was calculated using August 1st 2005 as the cut-off date.
  3. €Rounded to the nearest month.